The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
The CXCL8-CXCR1/2 pathways in cancer
Open accessAbstract
Persistent infection or chronic inflammation contributes significantly to tumourigenesis and tumour progression. C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctional cytokine to modulate tumour proliferation, invasion and migration in an autocrine or paracrine manner. Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including breast cancer, prostate cancer, lung cancer, colorectal carcinoma and melanoma. CXCL8 also integrates with multiple intracellular signalling pathways to produce coordinated effects. Neovascularisation, which provides a basis for fostering tumour growth and metastasis, is now recognised as a critical function of CXCL8 in the tumour microenvironment. In this review, we summarize the biological functions and clinical significance of the CXCL8 signalling axis in cancer. We also propose that CXCL8 may be a potential therapeutic target for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T. G., Bertoni, M., Bordoli, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku340 · Cited by 4,632
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., & Ferri, L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67484 · Cited by 1,395
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Multiple control of interleukin-8 gene expression
Hoffmann, E., Dittrich-Breiholz, O., Holtmann, H., & Kracht, M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.5.847 · Cited by 1,058 · cited 1×
“CXCL8 is almost undetectable in physiological states, but is rapidly induced by pro-inflammatory cytokines such as tumour necrosis factor a (TNFa) and interleukin-1b (IL-1b) [4].”
BackgroundMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Nozawa, H., Chiu, C., & Hanahan, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601807103 · Cited by 923
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar-Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 851
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
Brat, D. J., Bellail, A. C., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001061 · Cited by 760
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe-Jauffret, E., Birnbaum, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39397 · Cited by 747
Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Kuang, D.-M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., Yin, X.-Y., & Zheng, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.041 · Cited by 499
Jensen, H. K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F., & von der Maase, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9498 · Cited by 461
Structure of the chemokine receptor CXCR1 in phospholipid bilayers
Park, S. H., Das, B. B., Casagrande, F., Tian, Y., Nothnagel, H. J., Chu, M., Kiefer, H., Maier, K., De Angelis, A. A., Marassi, F. M., et al. (2012) · Nature · doi:10.1038/nature11580 · Cited by 457
Self-citationYasumoto, K., Okamoto, S., Mukaida, N., Murakami, S., Mai, M., & Matsushima, K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41701-2 · Cited by 448
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
van Hinsbergh, V. W. M., & Koolwijk, P. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm102 · Cited by 420
Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2463 · Cited by 417 · cited 5×
“Moreover, the CXCR1/2 blocking agent, Reparisxin, abolished the above effects of CXCL8 in vivo [38].”
BackgroundResultInfluentialInterleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
Luca, M., Huang, S., Gershenwald, J. E., Singh, R. K., Reich, R., & Bar‐Eli, M. (1997) · Europe PMC (PubMed Central) · Cited by 414
Ning, Y., Manegold, P. C., Hong, Y. K., Zhang, W., Pohl, A., Lurje, G., Winder, T., Yang, D., LaBonte, M. J., Wilson, P. M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25562 · Cited by 406
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.
Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D., & Strieter, R. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118734 · Cited by 403
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
David, J., Dominguez, C., Hamilton, D., & Palena, C. (2016) · Vaccines · doi:10.3390/vaccines4030022 · Cited by 395
Yalavarthi, S., Gould, T. J., Rao, A. N., Mazza, L. F., Morris, A. E., Núñez‐Álvarez, C., Hernández‐Ramírez, D., Bockenstedt, P. L., Liaw, P. C., Cabral, A. R., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39247 · Cited by 391
Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma.
Smith, D. R., Polverini, P. J., Kunkel, S. L., Orringer, M. B., Whyte, R. I., Burdick, M. D., Wilke, C. A., & Strieter, R. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.5.1409 · Cited by 373
Inoue, K., Slaton, J. W., Eve, B. Y., Kim, S. J., Perrotte, P., Balbay, M. D., Yano, S., Bar‐Eli, M., Radinsky, R., Pettaway, C. A., et al. (2000) · PubMed · Cited by 361
Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.-D., Gudas, J. M., & Bar-Eli, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64164-8 · Cited by 361
Benoy, I. H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpé, S., Vermeulen, P. B., & Dirix, L. Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0812 · Cited by 356
Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y.-L., Bowman, E. D., Engels, E. A., Caporaso, N. E., & Harris, C. C. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr216 · Cited by 333
Rao, H.-L., Chen, J.-W., Li, M., Xiao, Y.-B., Fu, J., Zeng, Y.-X., Cai, M.-Y., & Xie, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030806 · Cited by 327
Knall, C., Worthen, G. S., & Johnson, G. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3052 · Cited by 321
Fridlender, Z. G., Sun, J., Mishalian, I., Singhal, S., Cheng, G., Kapoor, V., Horng, W., Fridlender, G., Bayuh, R., Worthen, G. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031524 · Cited by 311
Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., De Cremoux, P., Bertheau, P., Badoual, C., Vielh, P., Larsen, A. K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2432 · Cited by 302
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
Donskov, F., & von der Maase, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9594 · Cited by 299
Li, A., Varney, M. L., Valasek, J., Godfrey, M., Dave, B. J., & Singh, R. K. (2005) · Angiogenesis · doi:10.1007/s10456-005-5208-4 · Cited by 285
Self-citationJensen, T. O., Schmidt, H., Møller, H. J., Donskov, F., Høyer, M., Sjoegren, P., Christensen, I. J., & Steiniche, T. (2012) · Cancer · doi:10.1002/cncr.26511 · Cited by 281
IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways
Schraufstatter, I. U., Chung, J., & Burger, M. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.280.6.l1094 · Cited by 278
Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer
Araki, S., Omori, Y., Lyn, D., Singh, R. K., Meinbach, D. M., Sandman, Y., Lokeshwar, V. B., & Lokeshwar, B. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1162 · Cited by 275
K-ras activation generates an inflammatory response in lung tumors
Ji, H., Houghton, A. M., Mariani, T. J., Perera, S., Kim, C. B., Padera, R., Tonon, G., McNamara, K., Marconcini, L. A., Hezel, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209237 · Cited by 271
Pak, A. S., Wright, M. A., Matthews, J. P., Collins, S. L., Petruzzelli, G. J., & Young, M. R. I. (1995) · PubMed · Cited by 271
Expression of interleukin-8 correlates with vascularity in human gastric carcinomas.
Kitadai, Y., Haruma, K., Sumii, K., Yamamoto, S., Ue, T., Yokozaki, H., Yasui, W., Ohmoto, Y., Kajiyama, G., Fidler, I. J., et al. (1998) · Europe PMC (PubMed Central) · Cited by 265
Mishalian, I., Bayuh, R., Eruslanov, E., Michaeli, J., Levy, L., Zolotarov, L., Singhal, S., Albelda, S. M., Granot, Z., & Fridlender, Z. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28770 · Cited by 253
Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P., & Kreutzer, D. L. (1998) · Urology · doi:10.1016/s0090-4295(97)00491-3 · Cited by 251
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells
Singh, J. K., Simões, B. M., Howell, S. J., Farnie, G., & Clarke, R. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3436 · Cited by 249
Sun, Z., & Yang, P. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01414-7 · Cited by 244
Bendre, M. S., Margulies, A. G., Walser, B., Akel, N. S., Bhattacharrya, S., Skinner, R. A., Swain, F., Ramani, V., Mohammad, K. S., Wessner, L. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2630 · Cited by 243
Wislez, M., Rabbe, N., Marchal-Sommé, J., Milleron, B. J., Crestani, B., Mayaud, C. M., Antoine, M., Soler, P., & Cadranel, J. L. (2003) · PubMed · Cited by 243
Knall, C., Young, S., Nick, J. A., Buhl, A. M., Worthen, G. S., & Johnson, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2832 · Cited by 242
Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., & Rak, J. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 237
Luppi, F., Longo, A. M., de Boer, W. I., Rabe, K. F., & Hiemstra, P. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.014 · Cited by 228
Singh, J. K., Farnie, G., Bundred, N. J., Simões, B. M., Shergill, A., Landberg, G., Howell, S. J., & Clarke, R. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1063 · Cited by 217
Ueda, T., Shimada, E., & Urakawa, T. (1994) · Journal of Gastroenterology · doi:10.1007/bf02361238 · Cited by 214
Chuntharapai, A., Lee, J., Hébert, C. A., & Kim, K. J. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.12.5682 · Cited by 211
Venkatakrishnan, G., Salgia, R., & Groopman, J. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6868 · Cited by 211
Murphy, C., McGurk, M., Pettigrew, J., Santinelli, A., Mazzucchelli, R., Johnston, P. G., Montironi, R., & Waugh, D. J. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1518 · Cited by 211
Li, X., Wang, S., Zhu, R., Li, H., Han, Q., & Zhao, R. C. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0269-y · Cited by 209
INTERLEUKIN-8 AS AN AUTOCRINE GROWTH FACTOR FOR HUMAN COLON CARCINOMA CELLS IN VITRO
Brew, R., Erikson, J. S., West, D. C., Kinsella, A. R., Slavin, J., & Christmas, S. E. (2000) · Cytokine · doi:10.1006/cyto.1999.0518 · Cited by 207
Interleukin-8 and MCAF: Novel Leukocyte Recruitment and Activating Cytokines
Matsushima, K., Baldwin, E. T., & Mukaida, N. (2015) · Chemical Immunology and Allergy · doi:10.1159/000420761 · Cited by 207
Kim, S. J., Uehara, H., Karashima, T., Mccarty, M., Shih, N., & Fidler, I. J. (2001) · Neoplasia · doi:10.1038/sj.neo.7900124 · Cited by 206
Lin, Y., Huang, R., Chen, L., Li, S., Shi, Q., Jordan, C., & Huang, R. (2004) · International Journal of Cancer · doi:10.1002/ijc.11724 · Cited by 205
IL‐8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer
Rotondo, R., Barisione, G., Mastracci, L., Grossi, F., Orengo, A. M., Costa, R., Truini, M., Fabbi, M., Ferrini, S., & Barbieri, O. (2009) · International Journal of Cancer · doi:10.1002/ijc.24448 · Cited by 198
Singh, R. K., & Lokeshwar, B. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2769 · Cited by 179
On the armament and appearances of human myeloid-derived suppressor cells
Poschke, I., & Kiessling, R. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.06.003 · Cited by 177
The Signaling and Biological Implications of FAK Overexpression in Cancer
Siesser, P. M. F., & Hanks, S. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0456 · Cited by 175
A Potential Role for Interleukin-8 in the Metastatic Phenotype of Breast Carcinoma Cells
De Larco, J. E., Wuertz, B. R. K., Rosner, K. A., Erickson, S. A., Gamache, D. E., Manivel, J. C., & Furcht, L. T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64005-9 · Cited by 173
Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer
Veltri, R. W., Miller, M. C., Zhao, G., Ng, A., Marley, G. M., Wright, G. L., Vessella, R. L., & Ralph, D. (1999) · Urology · doi:10.1016/s0090-4295(98)00455-5 · Cited by 169
Wang, J., Jia, Y., Wang, N., Zhang, X., Tan, B., Zhang, G., & Cheng, Y. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-7 · Cited by 166
Ning, Y., LaBonte, M. J., Zhang, W., Bohanes, P. O., Gerger, A., Yang, D., Benhaïm, L., Páez, D., Rosenberg, D. O., Venkata, K. C. N., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0915 · Cited by 162
Structure of a CXC chemokine-receptor fragment in complex with interleukin-8
Skelton, N. J., Quan, C., Reilly, D., & Lowman, H. (1999) · Structure · doi:10.1016/s0969-2126(99)80022-7 · Cited by 162
Singh, S., Sadanandam, A., Nannuru, K. C., Varney, M. L., Mayer‐Ezell, R., Bond, R. W., & Singh, R. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2387 · Cited by 160
Pǒld, M., Zhu, L. X., Sharma, S. P., Burdick, M. D., Lin, Y., Lee, P. P. N., Põld, A., Luo, J., Krysan, K., Dohadwala, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3262 · Cited by 160
Zhang, T., Tseng, C., Zhang, Y., Sirin, O., Corn, P. G., Li-Ning-Tapia, E. M., Troncoso, P., Davis, J., Pettaway, C., Ward, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11674 · Cited by 160
ITOH, Y., JOH, T., Tanida, S., SASAKI, M., KATAOKA, H., Itoh, K., OSHIMA, T., Ogasawara, N., Togawa, S., & WADA, T. (2005) · Cytokine · doi:10.1016/j.cyto.2004.11.005 · Cited by 159
Kitadai, Y., Takahashi, Y., Haruma, K., Naka, K., Sumii, K., Yokozaki, H., Yasui, W., Mukaida, N., Ohmoto, Y., Kajiyama, G., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690742 · Cited by 157
Mian, B. M., Dinney, C. P., Bermejo, C. E., Sweeney, P., Tellez, C. S., Yang, X., Gudas, J. M., McConkey, D. J., & Bar‐Eli, M. (2003) · PubMed · Cited by 148
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression
Gabellini, C., Trisciuoglio, D., Desideri, M., Candiloro, A., Ragazzoni, Y., Orlandi, A., Zupi, G., & Bufalo, D. D. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.007 · Cited by 145
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143
Zhao, H., Dupont, J., Yakar, S., Karas, M., & LeRoith, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207162 · Cited by 142
CXC‐chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer
Matsuo, Y., Raimondo, M., Woodward, T. A., Wallace, M. B., Gill, K. R., Tong, Z., Burdick, M. D., Yang, Z., Strieter, R. M., Hoffman, R. M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24383 · Cited by 140
Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases
Varney, M. L., Singh, S., Li, A., Mayer‐Ezell, R., Bond, R. W., & Singh, R. K. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.10.004 · Cited by 139
Self-citationCheng, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497104 · Cited by 139
Cheng, X., Li, Y., Tan, J. Y., Sun, B., Xiao, Y., Fang, X.-B., Zhang, X., Li, Q., Dong, J., Li, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.008 · Cited by 138
Modi, W. S., Dean, M. C., Seuánez, H., Mukaida, N., Matsushima, K., & O'Brien, S. (1990) · Human Genetics · doi:10.1007/bf00208938 · Cited by 134
IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration
Lee, L., Hellendall, R. P., Wang, Y., Haskill, J. S., Mukaida, N., Matsushima, K., & Ting, J. P. ‐. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2769 · Cited by 132
Interleukin‐8 modulates growth and invasiveness of estrogen receptor‐negative breast cancer cells
Yao, C., Lin, Y., Chua, M., Ye, C., Bi, J., Li, W., Zhu, Y., & Wang, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22930 · Cited by 132
Hubert, P., Heitzmann, A., Viel, S., Nicolas, A., Sastre‐Garau, X., Oppezzo, P., Pritsch, O., Osinaga, E., & Amigorena, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4222 · Cited by 132
Masuya, D., Huang, C., Liu, D., Kameyama, K., Hayashi, E., Yamauchi, A., Kobayashi, S., Haba, R., & Yokomise, H. (2001) · Cancer · doi:10.1002/1097-0142(20011115)92:10<2628::aid-cncr1616>3.0.co;2-f · Cited by 128
Wilson, C., Purcell, C., Seaton, A., Oladipo, O., Maxwell, P. J., O’Sullivan, J. M., Wilson, R. H., Johnston, P. G., & Waugh, D. J. J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143826 · Cited by 127
Yuan, A., Yu, C.-J., Luh, K.-T., Kuo, S.-H., Lee, Y.-C., & Yang, P.-C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.900 · Cited by 126
Scheibenbogen, C., hler, T. M., Häfele, J., HUNSTEIN, W., & Keilholz, U. (1995) · Melanoma Research · doi:10.1097/00008390-199506000-00006 · Cited by 125
Shi, Z., Yang, W., Chen, L., Yang, D., Zhou, Q., Zhu, J., Chen, J.-J., Huang, R., Chen, Z., & Huang, R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2196-0 · Cited by 122
Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer
Rubie, C. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i37.4996 · Cited by 121
MacManus, C. F., Pettigrew, J., Seaton, A., Wilson, C., Maxwell, P. J., Berlingeri, S., Purcell, C., McGurk, M., Johnston, P. G., & Waugh, D. J. J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0032 · Cited by 118
Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Wang, L., Cheng, G. Z., Park, S., Shu, S., He, L., Kong, W. W., Zhang, W., Yuan, Z., & Cheng, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497159 · Cited by 115
di Celle, P., Carbone, A., Marchis, G. M. D., Zhou, D., Sozzani, S., Zupo, S., Pini, M., Mantovani, A., & Foà, R. (1994) · Blood · doi:10.1182/blood.v84.1.220.220 · Cited by 113
Marjon, P., Bobrovnikova-Marjon, E. V., & Abcouwer, S. F. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-4 · Cited by 112
Src continues aging: current and future clinical directions
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111 · cited 1×
“CXCL8 signalling is positively correlated with an increase in phosphorylation of Src-kinases and FAK in cancer cells, which contributes to cell proliferation, cell survival, and chemoresistance [29,30].”
BackgroundWu, K., Katiyar, S., Li, A., Liu, M., Ju, X., Popov, V. M., Jiao, X., Lisanti, M. P., Casola, A., & Pestell, R. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802085105 · Cited by 108
Self-citationAnoxia-Induced Up-Regulation of Interleukin-8 in Human Malignant Melanoma
Kunz, M., Hartmann, A., Flory, E., Toksoy, A., Koczan, D., Thiesen, H., Mukaida, N., Neumann, M., Rapp, U. R., Bröcker, E., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65174-7 · Cited by 107
Singh, R. K., & Lokeshwar, B. L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-57 · Cited by 105
Molecular evolution of the human interleukin–8 receptor gene cluster
Ahuja, S. K., Özçelık, T., Milatovich, A., Francke, U., & Murphy, P. M. (1992) · Nature Genetics · doi:10.1038/ng0992-31 · Cited by 105
Xiao, Y., Yang, Z., Cheng, X., Fang, X.-B., Shen, T., Xia, C., Liu, P., Qian, H., Sun, B., Yin, Z., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.021 · Cited by 104
Snoussi, K., Mahfoudh, W., Bouaouina, N., Fekih, M., Khaïri, H., Helal, A. N., & Chouchane, L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-283 · Cited by 101
Wilson, C., Wilson, T. R., Johnston, P. G., Longley, D. B., & Waugh, D. J. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0148 · Cited by 100
Uehara, H., Troncoso, P., Johnston, D. A., Bucana, C. D., Dinney, C. P., Dong, Z., Fidler, I. J., & Pettaway, C. A. (2005) · The Prostate · doi:10.1002/pros.20223 · Cited by 99
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway
Chen, H., Sun, Y., Wu, C., Magyar, C. E., Li, X., Liang Cheng, C., Yao, J. L., Shen, S. S., Osunkoya, A. O., Liang, C. Y., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0368 · Cited by 98
Azenshtein, E., Meshel, T., Shina, S., Barak, N., Keydar, I., & Ben‐Baruch, A. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.05.024 · Cited by 92
Larco, J. E. D., Wuertz, B. R. K., Yee, D., Rickert, B. L., & Furcht, L. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2335921100 · Cited by 85
Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling
Brandolini, L., Cristiano, L., Fidoamore, A., Pizzol, M. D., Giacomo, E. D., Florio, T. M., Confalone, G., Galante, A., Cinque, B., Benedetti, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6234 · Cited by 83
Maxwell, P. J., Coulter, J. A., Walker, S. M., McKechnie, M., Neisen, J., McCabe, N., Kennedy, R. D., Salto‐Tellez, M., Albanese, C., & Waugh, D. J. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.032 · Cited by 82
Desai, S., Laskar, S. S., & Pandey, B. N. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.025 · Cited by 80
Thyroid follicular cells produce interleukin-8
Weetman, A. P., Bennett, G. L., & Wong, W. L. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.1.1619027 · Cited by 78
Ramjeesingh, R., Leung, R. M., & Siu, C. (2003) · The FASEB Journal · doi:10.1096/fj.02-0560fje · Cited by 78
Involvement of IL-8 in COX-2-Mediated Bone Metastases from Breast Cancer
Singh, B., Berry, J. A., Vincent, L., & Lucci, A. (2006) · Journal of Surgical Research · doi:10.1016/j.jss.2006.03.018 · Cited by 77
Lang, K., Niggemann, B., Zänker, K. S., & Entschladen, F. (2002) · International Journal of Cancer · doi:10.1002/ijc.10424 · Cited by 76
Dabkevičienė, D., Jonušienė, V., Žitkutė, V., Žalytė, E., Grigaitis, P., Kirvelienė, V., & Sasnauskienė, A. (2015) · Medical Oncology · doi:10.1007/s12032-015-0703-y · Cited by 68
Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans
Kamalakar, A., Bendre, M. S., Washam, C. L., Fowler, T. W., Carver, A. A., Dilley, J. D., Bracey, J. W., Akel, N. S., Margulies, A. G., Skinner, R. A., et al. (2014) · Bone · doi:10.1016/j.bone.2014.01.015 · Cited by 65
Kamohara, H., Takahashi, M., Ishiko, T., Ogawa, M., & Baba, H. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.3.627 · Cited by 62
Interleukin-8 promotes cell migration through integrin αvβ6 upregulation in colorectal cancer
Sun, Q., Sun, F., Wang, B., Liu, S., Niu, W., Liu, E., Peng, C., Wang, J., Gao, H., Liang, B., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.021 · Cited by 62
Freisinger, C. M., & Huttenlocher, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112183 · Cited by 59
Shiau, M., Fan, L.-C., Yang, S., Tsao, C.-H., Lee, H., Cheng, Y. W., Lai, L.-C., & Chang, Y.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054423 · Cited by 57
Taş, F., Duranyıldız, D., Oğuz, H., Çamlıca, H., Yasasever, V., & Topuz, E. (2006) · Cancer Investigation · doi:10.1080/07357900600814771 · Cited by 55
Hsu, Y., Hung, J., Ko, Y., Hung, C., Huang, M., & Kuo, P. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq030 · Cited by 54
Sunaga, N., Kaira, K., Tomizawa, Y., Shimizu, K., Imai, H., Takahashi, G., Kakegawa, S., Ohtaki, Y., Nagashima, T., Kasahara, N., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.110 · Cited by 50
Salcedo, R., Martins‐Green, M. M., Gertz, B., Oppenheim, J. J., & Murphy, W. J. (2002) · PubMed · Cited by 49
Regulation of interleukin 8 expression in human malignant melanoma cells.
Singh, R. K., & Varney, M. L. (1998) · PubMed · Cited by 48
Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells
Bi, L., Zhou, N., Cheng, L., Lu, F., Tian-Xin, L., Xuan, X., Chun, J., Jin-li, H., Huang, H. W., Zhang, C., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.018 · Cited by 47
Role of IL-8 induced angiogenesis in uveal melanoma
Lattanzio, L., Tonissi, F., Torta, I., Gianello, L., Russi, E. G., Milano, G. A., Merlano, M. C., & Nigro, C. L. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0005-1 · Cited by 44
König, B., Steinbach, F., Janocha, B., Drynda, A., Stümm, M., Philipp, C., Allhoff, E. P., & König, W. (1999) · PubMed · Cited by 44
Shao, N., Chen, L., Ye, R.-Y., Lin, Y., & Wang, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.022 · Cited by 43
Targeting IL-8 signalling to inhibit breast cancer stem cell activity
Singh, J. K., Simões, B. M., Clarke, R. B., & Bundred, N. J. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.835398 · Cited by 42
Chen, K., Wu, K., Jiao, X., Wang, L., Ju, X., Wang, M., Sante, G. D., Xu, S., Wang, Q., Li, K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0611 · Cited by 40
Self-citationInterleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations
Boldrini, L., Gisfredi, S., Ursino, S., Lucchi, M., Mussi, A., Basolo, F., Pingitore, R., & Fontanini, G. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.07.002 · Cited by 36
Gulumian, M. (1999) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006918212866 · Cited by 34
Gulumian, M. (1999) · Springer eBooks · doi:10.1007/978-1-4615-5097-6_8 · Cited by 33
Yuan, A., Yu, C., Luh, K., Kuo, S.-H., Lee, Y.-C., & Yang, P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.900 · Cited by 31
Milovanović, J., Todorović‐Raković, N., & Rabi, Z. A. (2013) · PubMed · Cited by 29
Uen, W.-C., Hsieh, C.-H., Tseng, T., Jiang, S. S., Tseng, J., & Lee, S.-C. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000134 · Cited by 19
Cited by
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Cambier, S., Gouwy, M., & Proost, P. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00974-6 · Cited by 591
Interleukin-8: An evolving chemokine
Matsushima, K., Yang, D., & Oppenheim, J. J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155828 · Cited by 520
Metadata
- Authors
- Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 31
- Pages
- 61-71
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W2512931560
- Cited by
- 662
- References
- 140
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.